A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis
Purpose: For patients with axillary bromhidrosis, it is not clear that whether a low response to initial botulinum toxin A (BTX-A) treatment is related to poor long-term outcomes. Patients and methods: From August 2011 to March 2016, 31 patients with primary axillary bromhidrosis were recruited. The...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-01-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1329512 |
| _version_ | 1797683739753447424 |
|---|---|
| author | Jinguang He Tao Wang Jiasheng Dong |
| author_facet | Jinguang He Tao Wang Jiasheng Dong |
| author_sort | Jinguang He |
| collection | DOAJ |
| description | Purpose: For patients with axillary bromhidrosis, it is not clear that whether a low response to initial botulinum toxin A (BTX-A) treatment is related to poor long-term outcomes. Patients and methods: From August 2011 to March 2016, 31 patients with primary axillary bromhidrosis were recruited. They had the duration of efficacy for less than 4 weeks (median, 3 weeks; range, 1–3 weeks) after the first BTX-A injection (50 U per underarm) and were considered to have a low response to BTX-A treatment. The second injection with the same dose was immediately administered once the symptoms recurred. Subsequent sessions were performed with a double dose. Results: The duration of efficacy rose significantly to 10 weeks (range, 1–24 weeks) after the second injection (p < .01). Twenty-five patients received the third injection. The resultant duration further increased to 16 weeks (range, 12–26 weeks). No patients reported adverse effects during our follow-up period. Conclusions: For patients with primary axillary bromhidrosis, a low initial BTX-A treatment response does not predict poor long-term outcomes. Immediate reinjection with the same dose and subsequent sessions with a double dose is a safe strategy and can increase the duration of BTX-A therapy. |
| first_indexed | 2024-03-12T00:20:13Z |
| format | Article |
| id | doaj.art-5cdf2c33e7cc44ce94ed51d1c61d9c5a |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:20:13Z |
| publishDate | 2018-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5cdf2c33e7cc44ce94ed51d1c61d9c5a2023-09-15T14:08:30ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-01-0129110210410.1080/09546634.2017.13295121329512A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosisJinguang He0Tao Wang1Jiasheng Dong2Shanghai 9th People’s Hospital, Shanghai JiaoTong University School of MedicineShanghai 9th People’s Hospital, Shanghai JiaoTong University School of MedicineShanghai 9th People’s Hospital, Shanghai JiaoTong University School of MedicinePurpose: For patients with axillary bromhidrosis, it is not clear that whether a low response to initial botulinum toxin A (BTX-A) treatment is related to poor long-term outcomes. Patients and methods: From August 2011 to March 2016, 31 patients with primary axillary bromhidrosis were recruited. They had the duration of efficacy for less than 4 weeks (median, 3 weeks; range, 1–3 weeks) after the first BTX-A injection (50 U per underarm) and were considered to have a low response to BTX-A treatment. The second injection with the same dose was immediately administered once the symptoms recurred. Subsequent sessions were performed with a double dose. Results: The duration of efficacy rose significantly to 10 weeks (range, 1–24 weeks) after the second injection (p < .01). Twenty-five patients received the third injection. The resultant duration further increased to 16 weeks (range, 12–26 weeks). No patients reported adverse effects during our follow-up period. Conclusions: For patients with primary axillary bromhidrosis, a low initial BTX-A treatment response does not predict poor long-term outcomes. Immediate reinjection with the same dose and subsequent sessions with a double dose is a safe strategy and can increase the duration of BTX-A therapy.http://dx.doi.org/10.1080/09546634.2017.1329512axillary bromhidrosisbotulinum toxin alow initial responsetreatment |
| spellingShingle | Jinguang He Tao Wang Jiasheng Dong A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis Journal of Dermatological Treatment axillary bromhidrosis botulinum toxin a low initial response treatment |
| title | A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis |
| title_full | A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis |
| title_fullStr | A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis |
| title_full_unstemmed | A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis |
| title_short | A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis |
| title_sort | low initial botulinum toxin a treatment response does not predict poor long term outcomes in patients with axillary bromhidrosis |
| topic | axillary bromhidrosis botulinum toxin a low initial response treatment |
| url | http://dx.doi.org/10.1080/09546634.2017.1329512 |
| work_keys_str_mv | AT jinguanghe alowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis AT taowang alowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis AT jiashengdong alowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis AT jinguanghe lowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis AT taowang lowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis AT jiashengdong lowinitialbotulinumtoxinatreatmentresponsedoesnotpredictpoorlongtermoutcomesinpatientswithaxillarybromhidrosis |